Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4968)
All Articles published online
|
Oct 1, 2004 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10(19): 2878-2882 [PMID: 15334691 DOI: 10.3748/wjg.v10.i19.2878] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i19/2878.htm |
| Number | Citing Articles |
| 1 |
Celina Ang, Sonia Reichert, Randall F. Holcombe. The American Cancer Society's Oncology in Practice. 2018; : 100 doi: 10.1002/9781118592168.ch7
|
| 2 |
Lin Li, Wenzhuo Zhao, Mengmeng Wang, Jie Hu, Enxin Wang, Yan Zhao, Lei Liu. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterology 2018; 18(1) doi: 10.1186/s12876-018-0849-0
|
| 3 |
Kenneth N. Huynh, Sriram Rao, Bradley Roth, Theodore Bryan, Dayantha M. Fernando, Farshid Dayyani, David Imagawa, Nadine Abi-Jaoudeh. Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma. Cancers 2023; 15(10): 2738 doi: 10.3390/cancers15102738
|
| 4 |
Stefano Ginanni Corradini, Sergio Morini, Francesca Liguori, Simone Carotti, Andrea Onetti Muda, Maria Antonella Burza, Maria Siciliano, Antonio Molinaro, Alfredo Cantafora, Ida Blotta, Manuela Merli, Pasquale Berloco, Massimo Rossi, Adolfo Francesco Attili, Eugenio Gaudio. Differential vascular endothelial growth factor A protein expression between small hepatocellular carcinoma and cirrhosis correlates with serum vascular endothelial growth factor A and α‐fetoprotein. Liver International 2009; 29(1): 103 doi: 10.1111/j.1478-3231.2008.01781.x
|
| 5 |
Andrea Casadei-Gardini, Orsi Giulia, Caputo Francesco, Ercolani Giorgio. Developments in predictive biomarkers for hepatocellular carcinoma therapy. Expert Review of Anticancer Therapy 2020; 20(1): 63 doi: 10.1080/14737140.2020.1712198
|
| 6 |
Kai-Wen Chen, Tzu-Ming Ou, Chin-Wen Hsu, Chi-Ting Horng, Ching-Chang Lee, Yuh-Yuan Tsai, Chi-Chang Tsai, Yi-Sheng Liou, Chen-Chieh Yang, Chao-Wen Hsueh, Wu-Hsien Kuo. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World Journal of Hepatology 2015; 7(10): 1412-1420 doi: 10.4254/wjh.v7.i10.1412
|
| 7 |
Jean-François Dufour. TACE with or without systemic therapy?. Journal of Hepatology 2012; 56(6): 1224 doi: 10.1016/j.jhep.2012.02.011
|
| 8 |
Yifan Tong, Zheyong Li, Yuelong Liang, Hong Yu, Xiao Liang, Hui Liu, Xiujun Cai. Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? a propensity score analysis. Oncotarget 2017; 8(16): 26671 doi: 10.18632/oncotarget.15793
|
| 9 |
Jun-Ning Liu, Ji-Jiang Li, Shu Yan, Guang-Nian Zhang, Peng-Sheng Yi. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1074793
|
| 10 |
AKIRA MIZUKI, MASAYUKI TATEMICHI, NOBUHIRO TSUKADA, RYOUSUKE NAGAMATSU, MITSUHIKO KAWAGUCHI, TATSUYA ITOSHIMA, SHIGEKI MARUYAMA, ATSUHIKO SATOU, YASUHISA IMARI, TOSHIHARU KAWATOKO, JUNYA SHIMONO, HIROSHI NAGATA. Addition of transcatheter arterial chemoembolization decreased local recurrence but had no survival benefit to percutaneous ethanol injection therapy for patients with small hepatocellular carcinoma: A multicenter randomized control study. Oncology Letters 2010; 1(5): 855 doi: 10.3892/ol_00000151
|
| 11 |
Riccardo Lencioni. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Critical Reviews in Oncology/Hematology 2012; 83(2): 216 doi: 10.1016/j.critrevonc.2011.10.008
|
| 12 |
Jiaping Li, Fujun Zhang, Jianyong Yang, Yingqiang Zhang, Yu Wang, Wenzhe Fan, Yonghui Huang, Wei Wang, Henry Ran, Shi Ke. Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study. Targeted Oncology 2015; 10(2): 287 doi: 10.1007/s11523-014-0338-5
|
| 13 |
Osamu Matsui. Current Status of Hepatocellular Carcinoma Treatment in Japan. Clinical Drug Investigation 2012; 32(S2): 3 doi: 10.1007/BF03265492
|
| 14 |
Yuk Ting Ma, Daniel H Palmer. Impact of restricting access to high-cost medications for hepatocellular carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research 2012; 12(4): 465 doi: 10.1586/erp.12.33
|
| 15 |
Minsig Choi, Jefrey J. Critchfield, Philip A. Philip. Combining sorafenib with chemoembolization for hepatocellular cancer. Community Oncology 2011; 8(5): 216 doi: 10.1016/S1548-5315(12)70013-X
|
| 16 |
Andreas Erhardt, Frank Kolligs, Matthias Dollinger, Eckart Schott, Hennig Wege, Michael Bitzer, Christiane Gog, Frank Lammert, Markus Schuchmann, Clemens Walter, Dirk Blondin, Christian Ohmann, Dieter Häussinger. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. Cancer Chemotherapy and Pharmacology 2014; 74(5): 947 doi: 10.1007/s00280-014-2568-8
|
| 17 |
Goshi Shiota, Norimasa Miura. Biomarkers for hepatocellular carcinoma. Clinical Journal of Gastroenterology 2012; 5(3): 177 doi: 10.1007/s12328-012-0301-x
|
| 18 |
Xinxiang Yang, Wai-Ho Oscar Yeung, Kel Vin Tan, Tak-Pan Kevin Ng, Li Pang, Jie Zhou, Jinyang Li, Changxian Li, Xiangcheng Li, Chung Mau Lo, Weiyuan John Kao, Kwan Man. Development of cisplatin-loaded hydrogels for trans-portal vein chemoembolization in an orthotopic liver cancer mouse model. Drug Delivery 2021; 28(1): 520 doi: 10.1080/10717544.2021.1895908
|
| 19 |
Shuang Liu, Lei Guo, Hui Li, Bo Zhang, Jialei Sun, Chenghao Zhou, Jian Zhou, Jia Fan, Qinghai Ye. Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus. Annals of Surgical Oncology 2018; 25(7): 2098 doi: 10.1245/s10434-018-6438-1
|
| 20 |
Haohao Lu, Chuansheng Zheng, Bin Liang, Xiangwen Xia, Hongjie Fan. Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1280837
|
| 21 |
Nadine Abi-Jaoudeh, Ben Sadeghi, Hanna Javan, Jim Na, Graham Beaton, Fabio Tucci, Satheesh Ravula, David K. Imagawa. Drug-Eluting Embolic Loaded with Tyrosine Kinase Inhibitor Targeted Therapies for Transarterial Chemoembolization in a VX2 Model. Cancers 2023; 15(12): 3236 doi: 10.3390/cancers15123236
|
| 22 |
Alice E. Hagan, Sami A. Znati, Rebecca Carter, Adam Westhorpe, Wendy M. Macfarlane, Gary J. Phillips, Andrew W. Lloyd, Ricky A. Sharma, Andrew L. Lewis. Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia. Anti-Cancer Drugs 2021; 32(9): 897 doi: 10.1097/CAD.0000000000001082
|
| 23 |
Norihiro Kokudo, Junta Nakajima, Etsuro Hatano, Kazushi Numata. Current Status of Hepatocellular Carcinoma Treatment in Japan. Clinical Drug Investigation 2012; 32: 25 doi: 10.2165/1163023-S0-000000000-00000
|
| 24 |
Zongren Ding, Guoxu Fang, Yanyan Tang, Yongyi Zeng. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-63571-1
|
| 25 |
Andrew X. Zhu, Dan G. Duda, Dushyant V. Sahani, Rakesh K. Jain. HCC and angiogenesis: possible targets and future directions. Nature Reviews Clinical Oncology 2011; 8(5): 292 doi: 10.1038/nrclinonc.2011.30
|
| 26 |
Bin-Yan Zhong, Zhi-Ping Yan, Jun-Hui Sun, Lei Zhang, Zhong-Heng Hou, Xiao-Li Zhu, Ling Wen, Cai-Fang Ni. Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Frontiers in Molecular Biosciences 2021; 8 doi: 10.3389/fmolb.2021.618050
|
| 27 |
Agneta Norén, Jozef Urdzik, Frans Duraj, Charlotte Ebeling Barbier, Britt-Mari Karlson, Ulf Haglund. Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. HPB 2010; 12(9): 637 doi: 10.1111/j.1477-2574.2010.00210.x
|
| 28 |
Satoru Murata, Takahiko Mine, Fumie Sugihara, Daisuke Yasui, Hidenori Yamaguchi, Tatsuo Ueda, Shiro Onozawa, Shin-ichiro Kumita. Interventional treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology 2014; 20(37): 13453-13465 doi: 10.3748/wjg.v20.i37.13453
|
| 29 |
Katrin Fuchs, Rafael Duran, Alban Denys, Pierre E. Bize, Gerrit Borchard, Olivier Jordan. Drug-eluting embolic microspheres for local drug delivery – State of the art. Journal of Controlled Release 2017; 262: 127 doi: 10.1016/j.jconrel.2017.07.016
|
| 30 |
C. Damiano Gadaleta, Girolamo Ranieri. Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. Critical Reviews in Oncology/Hematology 2011; 80(1): 40 doi: 10.1016/j.critrevonc.2010.10.005
|
| 31 |
Takamasa Ohki, Mayuko Kondo, Yuki Karasawa, Satoshi Kawamura, Shuuya Maeshima, Kentaro Kojima, Michiharu Seki, Nobuo Toda, Yoshinobu Shioda, Kazumi Tagawa. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index. Advances in Therapy 2017; 34(5): 1097 doi: 10.1007/s12325-017-0524-9
|
| 32 |
Nan Du, Guorong Jia, Wen Zhang, Qianqian Tong, Xudong Qu, Rong Liu, Danni Li, Zhiping Yan, Changjing Zuo, Xiao Li, Rou Li, Wei Zhang. One-day examination of triple nuclear medicine imaging and application in evaluating transarterial embolization. Heliyon 2024; 10(9): e29597 doi: 10.1016/j.heliyon.2024.e29597
|
| 33 |
Jia Yuan, Xin Yin, Bei Tang, Hui Ma, Lan Zhang, Lixin Li, Rongxin Chen, Xiaoying Xie, Zhenggang Ren. Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. BioMed Research International 2019; 2019: 1 doi: 10.1155/2019/2141859
|
| 34 |
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng. Transcatheter Arterial Chemoembolization Plus Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma: a Single-Arm, Phase II Trial. Future Oncology 2022; 18(30): 3367 doi: 10.2217/fon-2022-0188
|
| 35 |
Kaoru Tsuchiya, Yasuhiro Asahina, Shuya Matsuda, Masaru Muraoka, Toru Nakata, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Shoko Suzuki, Takanori Hosokawa, Takashi Nishimura, Ken Ueda, Teiji Kuzuya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Nobuyuki Enomoto, Namiki Izumi. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer 2014; 120(2): 229 doi: 10.1002/cncr.28384
|
| 36 |
Xueying Sun, Hongchi Jiang, Xian Jiang, Hongtao Tan, Qinghui Meng, Bei Sun, Ruian Xu, Geoffrey W. Krissansen. Antisense Hypoxia-Inducible Factor-1α Augments Transcatheter Arterial Embolization in the Treatment of Hepatocellular Carcinomas in Rats. Human Gene Therapy 2009; 20(4): 314 doi: 10.1089/hum.2008.164
|
| 37 |
Osamu Matsui. Current Status of Hepatocellular Carcinoma Treatment in Japan. Clinical Drug Investigation 2012; 32: 3 doi: 10.2165/1163021-S0-000000000-00000
|
| 38 |
Jean-François Dufour. Targeted Therapies for Hepatocellular Carcinoma. 2011; : 74 doi: 10.2217/ebo.11.287
|
| 39 |
Zhi-Huan Lin, Jun-Rong Jiang, Xiao-Kun Ma, Jie Chen, He-Ping Li, Xing Li, Xiang-Yuan Wu, Ming-Sheng Huang, Qu Lin. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma. Clinical and Experimental Medicine 2021; 21(1): 109 doi: 10.1007/s10238-020-00667-8
|
| 40 |
Girolamo Ranieri, Michele Ammendola, Ilaria Marech, Annamaria Laterza, Ines Abbate, Caroline Oakley, Angelo Vacca, Rosario Sacco, Cosmo Damiano Gadaleta. Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients. World Journal of Gastroenterology 2015; 21(19): 6018-6025 doi: 10.3748/wjg.v21.i19.6018
|
| 41 |
Yaoping Shi, Bo Zhai. A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma. Gastrointestinal Tumors 2016; 3(2): 90 doi: 10.1159/000445888
|
| 42 |
XiuPing Zhang, Kang Wang, Meng Wang, Guang Yang, XiaoFei Ye, MengChao Wu, ShuQun Cheng. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget 2017; 8(17): 29416 doi: 10.18632/oncotarget.15075
|
| 43 |
Yejing Zhu, Enxin Wang, Shoujie Zhao, Dandan Han, Yan Zhao, Hui Chen, Jun Zhu, Tenghui Han, Yang Bai, Yanju Lou, Yongchao Zhang, Man Yang, Luo Zuo, Jiahao Fan, Xing Chen, Jia Jia, Wenbin Wu, Weirong Ren, Tingting Bai, Shouzheng Ma, Fenghua Xu, Yuxin Tang, Ying Han, Junlong Zhao, Jing Li, Xilin Du, Dongfeng Chen, Lei Liu, Xingshun Qi. Identify Optimal Hap Series Scores for Unresectable HCC Patients Undergoing TACE Plus Sorafenib: A Chinese Multicenter Observational Study. SSRN Electronic Journal 2022; doi: 10.2139/ssrn.4150490
|
| 44 |
Hiro HORIKIRIZONO, Kumiko ISHIGAKI, Keigo IIZUKA, Kei TAMURA, Naoki SAKURAI, Kazuyuki TERAI, Tatsuya HEISHIMA, Orie YOSHIDA, Kazushi ASANO. Serum vascular endothelial growth factor in dogs with various proliferative diseases. Journal of Veterinary Medical Science 2022; 84(5): 720 doi: 10.1292/jvms.21-0509
|
| 45 |
Lei Liu, Hui Chen, Mengmeng Wang, Yan Zhao, Guohong Cai, Xingshun Qi, Guohong Han, Zhuoli Zhang. Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis. PLoS ONE 2014; 9(3): e91124 doi: 10.1371/journal.pone.0091124
|
| 46 |
Andrew S. Mikhail, Ayele H. Negussie, Michal Mauda-Havakuk, Joshua W. Owen, William F. Pritchard, Andrew L. Lewis, Bradford J. Wood. Drug-eluting embolic microspheres: State-of-the-art and emerging clinical applications. Expert Opinion on Drug Delivery 2021; 18(3): 383 doi: 10.1080/17425247.2021.1835858
|
| 47 |
Valeria R. Mas, Daniel G. Maluf, Kellie J. Archer, Kenneth C. Yanek, Robert A. Fisher. Angiogenesis Soluble Factors as Hepatocellular Carcinoma Noninvasive Markers for Monitoring Hepatitis C Virus Cirrhotic Patients Awaiting Liver Transplantation. Transplantation 2007; 84(10): 1262 doi: 10.1097/01.tp.0000287596.91520.1a
|
| 48 |
Xinhua Zou, Qingyu Xu, Ran You, Guowen Yin. Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. Journal of Hepatocellular Carcinoma 2023; : 267 doi: 10.2147/JHC.S399874
|
| 49 |
Antonio Nicolini, Silvia Crespi, Laura Martinetti. Drug delivery embolization systems: a physician's perspective. Expert Opinion on Drug Delivery 2011; 8(8): 1071 doi: 10.1517/17425247.2011.590472
|
| 50 |
Tzu-Rong Peng, Ta-Wei Wu, Chao-Chuan Wu, Sou-Yi Chang, Cheng-Yi Chan, Ching-Sheng Hsu. Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma. Tzu Chi Medical Journal 2022; 34(2): 219 doi: 10.4103/tcmj.tcmj_84_21
|
| 51 |
Bal Krishan Sharma, Radhika Srinivasan, Shweta Kapil, Bhupesh Singla, Nitin Saini, Yogesh Kumar Chawla, Anuradha Chakraborti, Ajay Duseja, Naveen Kalra, Radha Krishan Dhiman. Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma. Molecular and Cellular Biochemistry 2013; 383(1-2): 103 doi: 10.1007/s11010-013-1759-7
|
| 52 |
Jun Muto, Ken Shirabe, Keishi Sugimachi, Yoshihiko Maehara. Review of angiogenesis in hepatocellular carcinoma. Hepatology Research 2015; 45(1): 1 doi: 10.1111/hepr.12310
|
| 53 |
Soojeong Cho, Nam Gi Min, Wooram Park, Shin‐Hyun Kim, Dong‐Hyun Kim. Janus Microcarriers for Magnetic Field‐Controlled Combination Chemotherapy of Hepatocellular Carcinoma. Advanced Functional Materials 2019; 29(26) doi: 10.1002/adfm.201901384
|
| 54 |
Wen-Sheng Tzeng, Wei-Lin Teng, Pao-Hsien Huang, Tzu-Ching Lin, Feng-Lin Yen, Yow-Ling Shiue. Pterostilbene Nanoparticles Downregulate Hypoxia-Inducible Factors in Hepatoma Cells Under Hypoxic Conditions. International Journal of Nanomedicine 2021; : 867 doi: 10.2147/IJN.S282172
|
| 55 |
Ece Meram, Colin Harari, Gabe Shaughnessy, Martin Wagner, Chris L. Brace, Charles A. Mistretta, Michael A. Speidel, Paul F. Laeseke. Quantitative 4D-Digital Subtraction Angiography to Assess Changes in Hepatic Arterial Flow during Transarterial Embolization: A Feasibility Study in a Swine Model. Journal of Vascular and Interventional Radiology 2019; 30(8): 1286 doi: 10.1016/j.jvir.2019.01.018
|
| 56 |
Jeane Chen, Sarah B. White, Kathleen R. Harris, Weiguo Li, Jonathan W.T. Yap, Dong-Hyun Kim, Robert J. Lewandowski, Lonnie D. Shea, Andrew C. Larson. Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model. Biomaterials 2015; 61: 299 doi: 10.1016/j.biomaterials.2015.05.010
|
| 57 |
Giuseppe Cabibbo, Silvia Tremosini, Giovanni Galati, Giancarlo Mazza, Gennaro Gadaleta-Caldarola, Giuseppe Lombardi, Michela Antonucci, Rodolfo Sacco. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014; 14(7): 831 doi: 10.1586/14737140.2014.920694
|
| 58 |
Daniel B. Brown, Jean-Francois H. Geschwind, Michael C. Soulen, Steven F. Millward, David Sacks. Society of Interventional Radiology Position Statement on Chemoembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology 2006; 17(2): 217 doi: 10.1097/01.RVI.0000196277.76812.A3
|
| 59 |
Federica Ferraina, Alessandro Fogliati, Mauro Alessandro Scotti, Fabrizio Romano, Mattia Garancini, Cristina Ciulli. Lobar and Segmental Atrophy of the Liver: Differential Diagnoses and Treatments. Livers 2024; 4(3): 320 doi: 10.3390/livers4030023
|
| 60 |
Lin Zheng, Chen-Yang Guo, Cheng-Shi Chen, Jin-Cheng Xiao, Hong-Tao Hu, Hong-Tao Cheng, Deng-Wei Zong, Li Jiang, Hai-Liang Li. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study. Oncotarget 2017; 8(57): 97613 doi: 10.18632/oncotarget.18811
|
| 61 |
Haidong Ai, Ting Gong, Yongbiao Ma, Guixu Ma, Wei Ding, Weibao Ding, Wenjuan Wang, Xuelin Zhao. Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1358602
|
| 62 |
Bingran Yu, Ning Zhang, Yun Feng, Yongfa Zhang, Ti Zhang, Lu Wang. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2023; : 1735 doi: 10.2147/JHC.S431917
|
| 63 |
Stephen L Chan, Winnie Yeo. Targeted therapy of hepatocellular carcinoma: Present and future. Journal of Gastroenterology and Hepatology 2012; 27(5): 862 doi: 10.1111/j.1440-1746.2012.07096.x
|
| 64 |
CELINA ANG, DWIGHT OWEN, GHASSAN K. ABOU-ALFA. Clinical Interventional Oncology. 2014; : 88 doi: 10.1016/B978-1-4557-1221-2.00018-0
|
| 65 |
Stephen L. Chan, Winnie Yeo, Frankie Mo, Anthony W.H. Chan, Jane Koh, Leung Li, Edwin P. Hui, Charing C.N. Chong, Paul B.S Lai, Tony S.K. Mok, Simon C.H. Yu. A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer 2017; 123(20): 3977 doi: 10.1002/cncr.30825
|
| 66 |
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Michihisa Moriguchi, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Sadahisa Ogasawara, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Philip James Johnson, Yasuaki Arai. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer 2022; 11(4): 354 doi: 10.1159/000522547
|
| 67 |
Matthias Pinter, Wolfgang Sieghart, Monika Schmid, Bernhard Dauser, Gerald Prager, Hans Peter Dienes, Michael Trauner, Markus Peck‐Radosavljevic. Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF‐A expression in hepatocellular carcinoma. United European Gastroenterology Journal 2013; 1(4): 265 doi: 10.1177/2050640613496605
|
| 68 |
Steven Lahti, Johannes M. Ludwig, Minzhi Xing, Lingyi Sun, Dexing Zeng, Hyun S. Kim, Yi-Hsien Hsieh. In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma—A pilot study. PLOS ONE 2017; 12(4): e0174539 doi: 10.1371/journal.pone.0174539
|
| 69 |
Ioannis A Ziogas, Georgios Tsoulfas. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World Journal of Clinical Oncology 2017; 8(3): 203-213 doi: 10.5306/wjco.v8.i3.203
|
| 70 |
Xuhua Duan, Hao Li, Donglin Kuang, Pengfei Chen, Mengfan Zhang, Tengfei Li, Dechao Jiao, Yanliang Li, Xiang He, Cheng Xing, Haibo Wang, Yaoxian Liu, Limin Xie, Shixi Zhang, Qiang Zhang, Peixin Zhu, Yongchuang Chang, Jichen Xie, Jianzhuang Ren, Xinwei Han. Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial. Signal Transduction and Targeted Therapy 2024; 9(1) doi: 10.1038/s41392-024-02012-x
|
| 71 |
Yuki Tomozawa, Norihisa Nitta, Shinichi Ohta, Shobu Watanabe, Akinaga Sonoda, Ayumi Nitta-Seko, Keiko Tsuchiya, Kiyoshi Murata. Anti-tumor Effects of Sorafenib Administered at Different Time Points in Combination with Transarterial Embolization in a Rabbit VX2 Liver Tumor Model. CardioVascular and Interventional Radiology 2017; 40(11): 1763 doi: 10.1007/s00270-017-1719-9
|
| 72 |
Bao-Jiang Liu, Song Gao, Xu Zhu, Jian-Hai Guo, Xin Zhang, Hui Chen, Xiao-Dong Wang, Ren-Jie Yang. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2020; 12(6): 663-676 doi: 10.4251/wjgo.v12.i6.663
|
| 73 |
Joong-Won Park, Young Hwan Koh, Hyun Beom Kim, Hwi Young Kim, Sangbu An, Joon-Il Choi, Sang Myung Woo, Byung-Ho Nam. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. Journal of Hepatology 2012; 56(6): 1336 doi: 10.1016/j.jhep.2012.01.006
|
| 74 |
Katrin Fuchs, Andras Kiss, Pierre E. Bize, Rafael Duran, Alban Denys, Gérard Hopfgartner, Gerrit Borchard, Olivier Jordan. Mapping of drug distribution in the rabbit liver tumor model by complementary fluorescence and mass spectrometry imaging. Journal of Controlled Release 2018; 269: 128 doi: 10.1016/j.jconrel.2017.10.042
|
| 75 |
Ana-Maria Bucalau, Illario Tancredi, Gontran Verset. In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?. Cancers 2021; 13(20): 5129 doi: 10.3390/cancers13205129
|
| 76 |
Beom Kyung Kim, Seung Up Kim, Kyung Ah Kim, Yong Eun Chung, Myeong-Jin Kim, Mi-Suk Park, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Man Deuk Kim, Sung Il Park, Jong Yoon Won, Do Yun Lee, Kwang-Hyub Han. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. Journal of Hepatology 2015; 62(6): 1304 doi: 10.1016/j.jhep.2015.01.022
|
| 77 |
Andrew X. Zhu, Riad Salem. Combining Transarterial Chemoembolization With Radiofrequency Ablation for Hepatocellular Carcinoma: One Step Forward?. Journal of Clinical Oncology 2013; 31(4): 406 doi: 10.1200/JCO.2012.46.1897
|
| 78 |
Marcin Szemitko, Elzbieta Golubinska-Szemitko, Jerzy Sienko, Aleksander Falkowski. Complications Following Irinotecan-Loaded Microsphere Chemoembolization of Colorectal Metastatic Liver Lesions Associated with Hepatic-Artery Branch Temporary Stasis. Current Oncology 2021; 28(3): 2296 doi: 10.3390/curroncol28030211
|
| 79 |
Jean-Marc Idée, Boris Guiu. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. Critical Reviews in Oncology/Hematology 2013; 88(3): 530 doi: 10.1016/j.critrevonc.2013.07.003
|
| 80 |
Timothy M. Pawlik, Diane K. Reyes, David Cosgrove, Ihab R. Kamel, Nikhil Bhagat, Jean-Francois H. Geschwind. Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma. Journal of Clinical Oncology 2011; 29(30): 3960 doi: 10.1200/JCO.2011.37.1021
|
| 81 |
Jian-hai Guo, Xu Zhu, Xiao-ting Li, Ren-jie Yang. Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Chinese Journal of Cancer Research 2012; 24(1): 36 doi: 10.1007/s11670-012-0036-8
|
| 82 |
Guiliang Wang, Yan Liu, Shu-feng Zhou, Ping Qiu, Linfang Xu, Ping Wen, Jianbo Wen, Xianzhong Xiao. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatology International 2016; 10(3): 501 doi: 10.1007/s12072-015-9700-7
|
| 83 |
Ming‐Yen Hsieh, Zu‐Yau Lin, Wan‐Long Chuang. Serial serum VEGF‐A, angiopoietin‐2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. The Kaohsiung Journal of Medical Sciences 2011; 27(8): 314 doi: 10.1016/j.kjms.2011.03.008
|
| 84 |
Ryan C. Perez, DaeHee Kim, Aaron W. P. Maxwell, Juan C. Camacho. Functional Imaging of Hypoxia: PET and MRI. Cancers 2023; 15(13): 3336 doi: 10.3390/cancers15133336
|
| 85 |
Shu Zhao, Minhang Zhou, Peng Wang, Jing Yang, Dong Zhang, Fan Yin, Peng Song. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis. Technology in Cancer Research & Treatment 2022; 21 doi: 10.1177/15330338221133640
|
| 86 |
Man Yang, Jin-Qiu Yuan, Ming Bai, Guo-Hong Han. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Molecular Biology Reports 2014; 41(10): 6575 doi: 10.1007/s11033-014-3541-7
|
| 87 |
Chang Jin Yoon, Jin Wook Chung. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set. 2017; : 1398 doi: 10.1016/B978-0-323-34062-5.00096-0
|
| 88 |
Ju Hyun Shim, Joong‐Won Park, Ji Hoon Kim, Min An, Sun‐Young Kong, Byung‐Ho Nam, Joon‐Il Choi, Hyun Beom Kim, Woo Jin Lee, Chang‐Min Kim. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Science 2008; 99(10): 2037 doi: 10.1111/j.1349-7006.2008.00909.x
|
| 89 |
Seiichi Mawatari, Tsutomu Tamai, Kotaro Kumagai, Akiko Saisyoji, Kaori Muromachi, Ai Toyodome, Ohki Taniyama, Haruka Sakae, Sho Ijuin, Kazuaki Tabu, Kohei Oda, Yasunari Hiramine, Akihiro Moriuchi, Kazuhiro Sakurai, Shuji Kanmura, Akio Ido. Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. Cancers 2022; 14(24): 6139 doi: 10.3390/cancers14246139
|
| 90 |
Yashwant Patidar, Karamvir Chandel, Naveen K. Condati, Shyam V. Srinivasan, Amar Mukund, Shiv K. Sarin. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma – A Retrospective Study. Journal of Clinical and Experimental Hepatology 2022; 12(3): 745 doi: 10.1016/j.jceh.2021.12.009
|
| 91 |
Tsutomu Tamai, Kotaro Kumagai, Haruka Sakae, Hiroka Onishi, Kazuaki Tabu, Eriko Tabu, Kaori Muromachi, Akiko Saishoji, Kohei Oda, Seiichi Mawatari, Akihiro Moriuchi, Kazuhiro Sakurai, Akio Ido. Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco‑regional control?. Molecular and Clinical Oncology 2017; doi: 10.3892/mco.2017.1434
|
| 92 |
O. Abdel-Rahman, Z. A. Elsayed. Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature. Digestive Diseases and Sciences 2013; 58(12): 3389 doi: 10.1007/s10620-013-2872-x
|
| 93 |
Hidekatsu Kuroda, Takayoshi Oikawa, Masashi Ninomiya, Masashi Fujita, Kazumichi Abe, Kazuo Okumoto, Tomohiro Katsumi, Wataru Sato, Go Igarashi, Chikara Iino, Tetsu Endo, Nobukazu Tanabe, Hiroshi Numao, Shinsaku Fukuda, Katsunori Iijima, Atsushi Masamune, Hiromasa Ohira, Yoshiyuki Ueno, Yasuhiro Takikawa. Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy. Liver Cancer 2022; 11(4): 383 doi: 10.1159/000522424
|
| 94 |
Jing Zhao, Dapeng Li, Yue Shi, Fengling Shi, Chengting Feng, Wei Li, Min Tao, Rongrui Liang. Transarterial Infusion Chemotherapy With and Without Embolisation in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. Annals of the Academy of Medicine, Singapore 2017; 46(5): 174 doi: 10.47102/annals-acadmedsg.V46N5p174
|
| 95 |
Jean-François Dufour, Hanno Hoppe, Markus H. Heim, Beat Helbling, Olivier Maurhofer, Zsolt Szucs-Farkas, Ralph Kickuth, Markus Borner, Daniel Candinas, Bettina Saar. Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study. The Oncologist 2010; 15(11): 1198 doi: 10.1634/theoncologist.2010-0180
|
| 96 |
Guohong Han, Jijin Yang, Guoliang Shao, Gaojun Teng, Maoqiang Wang, Jianyong Yang, Zhaoyu Liu, Gansheng Feng, Renjie Yang, Ligong Lu, Yee Chao, Jianhua Wang. Sorafenib in Combination with Transarterial Chemoembolization in Chinese Patients with Hepatocellular Carcinoma: A Subgroup Interim Analysis of the START Trial. Future Oncology 2013; 9(3): 403 doi: 10.2217/fon.13.11
|
| 97 |
Adam Hatzidakis, Lukas Müller, Miltiadis Krokidis, Roman Kloeckner. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers 2022; 14(10): 2469 doi: 10.3390/cancers14102469
|
| 98 |
Timo Alexander Auer, Federico Collettini. Transarterial Chemoembolization (TACE). 2023; : 65 doi: 10.1007/978-3-031-36261-3_8
|
| 99 |
Bruno M Strebel, Jean-François Dufour. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Review of Anticancer Therapy 2008; 8(11): 1743 doi: 10.1586/14737140.8.11.1743
|
| 100 |
Zhan-Qi Wei, Yue-Wei Zhang. Transcatheter arterial chemoembolization followed by surgical resection for hepatocellular carcinoma: a focus on its controversies and screening of patients most likely to benefit. Chinese Medical Journal 2021; 134(19): 2275 doi: 10.1097/CM9.0000000000001767
|
| 101 |
Chang-Hsien Liu, Cheng-Ming Peng, Jen-I. Hwang, Po-Chin Liang, Pei-Jer Chen, Nadine Abi-Jaoudeh, Lung-Hui Giiang, Yu-Shen Tyan. Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2022; 33(8): 926 doi: 10.1016/j.jvir.2022.04.031
|
| 102 |
Katrin Fuchs, Pierre E. Bize, Olivier Dormond, Alban Denys, Eric Doelker, Gerrit Borchard, Olivier Jordan. Drug-Eluting Beads Loaded with Antiangiogenic Agents for Chemoembolization: In Vitro Sunitinib Loading and Release and In Vivo Pharmacokinetics in an Animal Model. Journal of Vascular and Interventional Radiology 2014; 25(3): 379 doi: 10.1016/j.jvir.2013.11.039
|
| 103 |
Mario Petrillo, Francesca Patella, Filippo Pesapane, Matteo B Suter, Anna M Ierardi, Salvatore A Angileri, Chiara Floridi, Massimo de Filippo, Gianpaolo Carrafiello. Hypoxia and Tumor Angiogenesis in the Era of Hepatocellular Carcinoma Transarterial Loco-Regional Treatments. Future Oncology 2018; 14(28): 2957 doi: 10.2217/fon-2017-0739
|
| 104 |
Pamela Romanque, Anne-Christine Piguet, Jean-François Dufour. Targeting vessels to treat hepatocellular carcinoma. Clinical Science 2008; 114(7): 467 doi: 10.1042/CS20070310
|
| 105 |
Masashi Hirooka, Atsushi Hiraoka, Hironori Ochi, Yoshiyasu Kisaka, Kouji Joko, Kojiro Michitaka, Yoichi Hiasa. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma. American Journal of Roentgenology 2018; 210(4): 891 doi: 10.2214/AJR.17.18177
|
| 106 |
You-Bing Zheng, Qing-Wen Meng, Wei Zhao, Bing Liu, Jian-Wen Huang, Xu He, Yong Li, Bao-Shan Hu, Li-Gong Lu. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Medical Oncology 2014; 31(3) doi: 10.1007/s12032-014-0843-5
|
| 107 |
Gemma Bruera, Katia Cannita, Aldo Victor Giordano, Rosa Manetta, Roberto Vicentini, Sergio Carducci, Patrizia Saltarelli, Nerio Iapadre, Gino Coletti, Corrado Ficorella, Enrico Ricevuto. Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/806391
|
| 108 |
Kayoko Kasuya, Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, Yuta Kobayashi, Akira Kajiwara, Soichi Iritani, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Kenji Ikeda, Yasuji Arase, Yuichiro Eguchi, Masaji Hashimoto, Hiromitsu Kumada. Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib. Internal Medicine 2021; 60(3): 345 doi: 10.2169/internalmedicine.5185-20
|
| 109 |
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Kohichiroh Yasui, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Osamu Yokosuka, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Philip James Johnson, Yasuaki Arai. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69(8): 1492 doi: 10.1136/gutjnl-2019-318934
|
| 110 |
Dandan Wang, Jinfeng Zhang, Huijie Jiang. Development of predictive biomarkers for transarterial chemoembolization efficacy in hepatocellular carcinoma. Radiology of Infectious Diseases 2023; 10(3): 93 doi: 10.4103/rid.RID-D-23-00005
|
| 111 |
T. Pan, X.-S. Li, Q.-K. Xie, J.-P. Wang, W. Li, P.-H. Wu, M. Zhao. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. Clinical Radiology 2014; 69(12): e553 doi: 10.1016/j.crad.2014.09.007
|
| 112 |
Piao-Piao Jin, Shi-Yi Shao, Wang-Teng Wu, Xin-Yu Zhao, Bing-Feng Huang, Qi-Han Fu, Ri-Sheng Que, Qi-Da Hu. Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis. Japanese Journal of Clinical Oncology 2018; 48(12): 1058 doi: 10.1093/jjco/hyy138
|
| 113 |
Young‐Hwa Chung, Guohong Han, Jung‐Hwan Yoon, Jijin Yang, Jianhua Wang, Guo‐Liang Shao, Byung Ik Kim, Teng‐Yu Lee, Yee Chao. Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. International Journal of Cancer 2013; 132(10): 2448 doi: 10.1002/ijc.27925
|
| 114 |
Ghassan K. Abou-Alfa. TACE and Sorafenib: A Good Marriage?. Journal of Clinical Oncology 2011; 29(30): 3949 doi: 10.1200/JCO.2011.37.9651
|
| 115 |
Fujimasa Tada, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada. Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices. Journal of Gastroenterology 2023; 58(11): 1134 doi: 10.1007/s00535-023-02026-2
|
| 116 |
Xiang Li, Guangwei He, Feng Su, Zhaoxing Chu, Leiming Xu, Yazhong Zhang, Jianping Zhou, Yang Ding. Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma. Asian Journal of Pharmaceutical Sciences 2020; 15(6): 739 doi: 10.1016/j.ajps.2020.01.001
|
| 117 |
Rafael Duran, Sahar Mirpour, Vasily Pekurovsky, Shanmugasundaram Ganapathy-Kanniappan, Cory F. Brayton, Toby C. Cornish, Boris Gorodetski, Juvenal Reyes, Julius Chapiro, Rüdiger E. Schernthaner, Constantine Frangakis, MingDe Lin, Jessica D. Sun, Charles P. Hart, Jean-François Geschwind. Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. Clinical Cancer Research 2017; 23(2): 536 doi: 10.1158/1078-0432.CCR-16-0725
|
| 118 |
Shigeo Shimose, Hideki Iwamoto, Masatoshi Tanaka, Takashi Niizeki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Masahito Nakano, Hideya Suga, Taizo Yamaguchi, Takumi Kawaguchi, Ryoko Kuromatsu, Kazunori Noguchi, Hironori Koga, Takuji Torimura. Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers 2021; 13(1): 160 doi: 10.3390/cancers13010160
|
| 119 |
Rui Zhang, Yan-Hui Liu, Yu Li, Nan-Nan Li, Zheng Li. Present and prospect of transarterial chemoembolization combined with tyrosine kinase inhibitor and PD-1 inhibitor for unresectable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(11): 4315-4320 doi: 10.4251/wjgo.v16.i11.4315
|
| 120 |
Cheng-Shi Chen, Fang-Kun Li, Chen-Yang Guo, Jin-Cheng Xiao, Hong-Tao Hu, Hong-Tao Cheng, Lin Zheng, Deng-Wei Zong, Jun-Li Ma, Li Jiang, Hai-Liang Li. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Oncotarget 2016; 7(6): 7241 doi: 10.18632/oncotarget.6892
|
| 121 |
Yejing Zhu, Enxin Wang, Shoujie Zhao, Dandan Han, Yan Zhao, Hui Chen, Jun Zhu, Tenghui Han, Yang Bai, Yanju Lou, Yongchao Zhang, Man Yang, Luo Zuo, Jiahao Fan, Xing Chen, Jia Jia, Wenbin Wu, Weirong Ren, Tingting Bai, Shouzheng Ma, Fenghua Xu, Yuxin Tang, Ying Han, Junlong Zhao, Xingshun Qi, Jing Li, Xilin Du, Dongfeng Chen, Lei Liu. Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study. Frontiers in Oncology 2023; 12 doi: 10.3389/fonc.2022.983554
|
| 122 |
Wenchao Hu, Guohong Cao, Shengli Ye, Jianfeng Xu, Jing Chen, Guoliang Shao. Quantitative analysis with multiphase contrast-enhanced computed tomography to evaluate residual tumor activity of hepatocellular carcinoma after DEB-TACE. Medicine 2023; 102(24): e34054 doi: 10.1097/MD.0000000000034054
|
| 123 |
Wang Yao, Miao Xue, Mingjian Lu, Yu Wang, Yue Zhao, Yanqin Wu, Wenzhe Fan, Jiaping Li. Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.574668
|
| 124 |
Marcin Szemitko, Elzbieta Golubinska-Szemitko, Marcin Warakomski, Aleksander Falkowski. Evaluation of CRC-Metastatic Hepatic Lesion Chemoembolization with Irinotecan-Loaded Microspheres, According to the Site of Embolization. Journal of Personalized Medicine 2022; 12(3): 414 doi: 10.3390/jpm12030414
|
| 125 |
Xinhua Zou, Wenzhe Fan, Miao Xue, Jiaping Li. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Management and Research 2021; : 4013 doi: 10.2147/CMAR.S304591
|
| 126 |
Katerina Malagari, Efthimia Alexopoulou, Katerina Chatzimichail, Brenda Hall, John Koskinas, Samantha Ryan, Eva Gallardo, Alexis Kelekis, Athanassios Gouliamos, Dimitrios Kelekis. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdominal Imaging 2008; 33(5): 512 doi: 10.1007/s00261-007-9334-x
|
| 127 |
|
| 128 |
Jun Deng, Feng Wen. Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate‐Stage Hepatocellular Carcinoma, What Else Can We Do?. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.824799
|
| 129 |
Masatoshi Kudo, Kazuho Imanaka, Nobuyuki Chida, Kohei Nakachi, Won-Young Tak, Tadatoshi Takayama, Jung-Hwan Yoon, Takeshi Hori, Hiromitsu Kumada, Norio Hayashi, Shuichi Kaneko, Hirohito Tsubouchi, Dong Jin Suh, Junji Furuse, Takuji Okusaka, Katsuaki Tanaka, Osamu Matsui, Michihiko Wada, Iku Yamaguchi, Toshio Ohya, Gerold Meinhardt, Kiwamu Okita. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. European Journal of Cancer 2011; 47(14): 2117 doi: 10.1016/j.ejca.2011.05.007
|
| 130 |
Xuelian Cheng, Jingjing Li, Limei Feng, Songwei Feng, Xiao Wu, Yongming Li. The role of hypoxia-related genes in TACE-refractory hepatocellular carcinoma: Exploration of prognosis, immunological characteristics and drug resistance based on onco-multi-OMICS approach. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1011033
|
| 131 |
Kazuo Asano, Ken Kageyama, Akira Yamamoto, Atsushi Jogo, Sawako Uchida-Kobayashi, Etsuji Sohgawa, Kazuki Murai, Norifumi Kawada, Yukio Miki. Transcatheter Arterial Chemoembolization for Treatment-Naive Hepatocellular Carcinoma Has Different Treatment Effects Depending on Central or Peripheral Tumor Location. Liver Cancer 2023; 12(6): 576 doi: 10.1159/000530441
|
| 132 |
Koichiro Yamakado. 3. Transarterial Chemoembolization. Nihon Naika Gakkai Zasshi 2014; 103(1): 87 doi: 10.2169/naika.103.87
|
| 133 |
Samdeep K. Mouli, Laura W. Goff. Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. Current Treatment Options in Oncology 2017; 18(11) doi: 10.1007/s11864-017-0509-6
|
| 134 |
Hai-Hong Ye, Jia-Zhou Ye, Zhi-Bo Xie, Yu-Chong Peng, Jie Chen, Liang Ma, Tao Bai, Jun-Ze Chen, Zhan Lu, Hong-Gui Qin, Bang-De Xiang, Le-Qun Li. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. World Journal of Gastroenterology 2016; 22(13): 3632-3643 doi: 10.3748/wjg.v22.i13.3632
|
| 135 |
Daniel B. Brown, Jean-Francois H. Geschwind, Michael C. Soulen, Steven F. Millward, David Sacks. Society of Interventional Radiology Position Statement on Chemoembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology 2009; 20(7): S317 doi: 10.1016/j.jvir.2009.04.015
|
| 136 |
Gisèle N'Kontchou, Olivier Seror, Michel Beaugrand. Clinical Dilemmas in Primary Liver Cancer. 2011; : 125 doi: 10.1002/9781119962205.ch18
|
| 137 |
Ahmed O. Kaseb, Amr Hanbali, Matthew Cotant, Manal M. Hassan, Ira Wollner, Philip A. Philip. Vascular endothelial growth factor in the management of hepatocellular carcinoma. Cancer 2009; 115(21): 4895 doi: 10.1002/cncr.24537
|
| 138 |
Ghassan K. Abou-Alfa, William Jarnagin, Imane El Dika, Michael D'Angelica, Maeve Lowery, Karen Brown, Emmy Ludwig, Nancy Kemeny, Anne Covey, Christopher H. Crane, James Harding, Jinru Shia, Eileen M. O'Reilly. Abeloff's Clinical Oncology. 2020; : 1314 doi: 10.1016/B978-0-323-47674-4.00077-3
|
| 139 |
Lei Wang, Qiao Ke, Nanping Lin, Qizhen Huang, Yongyi Zeng, Jingfeng Liu. The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. International Journal of Hyperthermia 2019; 36(1): 1287 doi: 10.1080/02656736.2019.1692148
|
| 140 |
Tyler Sandow, Daniel DeVun, Paul Gulotta, Humberto Bohorquez, David Kirsch. Elevated Lung Shunt Fraction as a Prognostic Indicator for Disease Progression and Metastasis in Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2016; 27(6): 804 doi: 10.1016/j.jvir.2016.01.129
|
| 141 |
Xinjian Xu, Yiwen Ding, Tianfan Pan, Feng Gao, Xiangzhong Huang, Qiulian Sun. CT-Guided 125I Brachytherapy in the Treatment of Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study. Cancer Management and Research 2021; : 3317 doi: 10.2147/CMAR.S305422
|
| 142 |
Martin-Walter Welker, Stephan Zangos, Susanne Kriener, Christian Mönch, Stefan Zeuzem, Joerg Trojan. Sequential Therapy of Transarterial Chemoembolisation and Sorafenib in Intermediate Stage Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer 2010; 41(2): 149 doi: 10.1007/s12029-010-9146-z
|
| 143 |
Ronnie T. P. Poon, Cecilia Lau, Roberta Pang, Kelvin K. Ng, Jimmy Yuen, Sheung Tat Fan. High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies. Annals of Surgical Oncology 2007; 14(6): 1835 doi: 10.1245/s10434-007-9366-z
|
| 144 |
Carolyn D Britten, Antoinette S Gomes, Zev A Wainberg, David Elashoff, Rafael Amado, Yan Xin, Ronald W Busuttil, Dennis J Slamon, Richard S Finn. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study. BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-16
|
| 145 |
Roberto Minici, Michele Ammendola, Francesco Manti, Maria Anna Siciliano, Marco Minici, Iman Komaei, Giuseppe Currò, Domenico Laganà. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.634087
|
| 146 |
Weiguang Xu, Jung-Hee Kwon, Young Ho Moon, Young Bae Kim, Yun Suk Yu, Namgyu Lee, Kwan Yong Choi, Yun Soo Kim, Yong Keun Park, Bong Wan Kim, Hee Jung Wang. Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2014; 140(9): 1507 doi: 10.1007/s00432-014-1713-4
|
| 147 |
John T. Miura, T. Clark Gamblin. Transarterial Chemoembolization for Primary Liver Malignancies and Colorectal Liver Metastasis. Surgical Oncology Clinics of North America 2015; 24(1): 149 doi: 10.1016/j.soc.2014.09.004
|
| 148 |
Xin Yin, Lan Zhang, Yan-Hong Wang, Bo-Heng Zhang, Yu-Hong Gan, Ning-Lin Ge, Yi Chen, Li-Xin Li, Zheng-Gang Ren. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-849
|
| 149 |
John K. O'Connor, James Trotter, Gary L. Davis, Jane Dempster, Goran B. Klintmalm, Robert M. Goldstein. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transplantation 2012; 18(8): 949 doi: 10.1002/lt.23439
|
| 150 |
Hongchi Jiang, Qinghui Meng, Hongtao Tan, Shangha Pan, Bei Sun, Ruian Xu, Xueying Sun. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. International Journal of Cancer 2007; 121(2): 416 doi: 10.1002/ijc.22655
|
| 151 |
Lukas Müller, Fabian Stoehr, Aline Mähringer-Kunz, Felix Hahn, Arndt Weinmann, Roman Kloeckner. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. Journal of Hepatocellular Carcinoma 2021; : 403 doi: 10.2147/JHC.S285735
|
| 152 |
Wolfgang Sieghart, Matthias Pinter, Bernhard Dauser, Natalya Rohr-Udilova, Anne-Christine Piguet, Gerald Prager, Hubert Hayden, Hans-Peter Dienes, Jean-Francois Dufour, Markus Peck-Radosavljevic. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. Journal of Hepatology 2012; 57(3): 592 doi: 10.1016/j.jhep.2012.04.034
|
| 153 |
Fengjiao Zhao, Yong Zhou, Poshita Kumari Seesaha, Yihong Zhang, Siqin Liu, Xiaoyan Gan, Jun Hu, Yanhong Gu, Xiaofeng Chen. Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation. Medicine 2020; 99(38): e22312 doi: 10.1097/MD.0000000000022312
|
| 154 |
YOICHI YANO, FUMIHIKO YAMASHITA, KOTARO KUWAKI, KAZUTA FUKUMORI, OSAMU KATO, KAZUMITSU KIYOMATSU, TAKENORI SAKAI, HIROSHI YAMAMOTO, FUMIO YAMASAKI, EIJI ANDO, MICHIO SATA. Partial Spontaneous Regression of Hepatocellular Carcinoma: A Case with High Concentrations of Serum Lens Culinaris Agglutinin-reactive Alpha Fetoprotein. The Kurume Medical Journal 2005; 52(3): 97 doi: 10.2739/kurumemedj.52.97
|
| 155 |
Izumi Miki, Satoru Murata, Fumio Uchiyama, Daisuke Yasui, Tatsuo Ueda, Fumie Sugihara, Hidemasa Saito, Hidenori Yamaguchi, Ryusuke Murakami, Chiaki Kawamoto, Eiji Uchida, Shin-ichiro Kumita. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy. World Journal of Gastroenterology 2017; 23(35): 6437-6447 doi: 10.3748/wjg.v23.i35.6437
|
| 156 |
Bin-Yan Zhong, Cai-Fang Ni, Li Chen, Hai-Dong Zhu, Gao-Jun Teng. Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma. Radiology 2017; 284(2): 583 doi: 10.1148/radiol.2017161975
|
| 157 |
Alexander Gross, Thomas Albrecht. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. CardioVascular and Interventional Radiology 2020; 43(3): 402 doi: 10.1007/s00270-019-02364-w
|
| 158 |
Yan-Yu Wang, Xu Yang, Yun-Chao Wang, Jun-Yu Long, Hui-Shan Sun, Yi-Ran Li, Zi-Yu Xun, Nan Zhang, Jing-Nan Xue, Cong Ning, Jun-Wei Zhang, Cheng-Pei Zhu, Long-Hao Zhang, Xiao-Bo Yang, Hai-Tao Zhao. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. World Journal of Gastroenterology 2023; 29(10): 1614-1626 doi: 10.3748/wjg.v29.i10.1614
|
| 159 |
Asmaa I Gomaa, Imam Waked. Recent advances in multidisciplinary management of hepatocellular carcinoma. World Journal of Hepatology 2015; 7(4): 673-687 doi: 10.4254/wjh.v7.i4.673
|
| 160 |
Satoru Murata, Takahiko Mine, Tatsuo Ueda, Ken Nakazawa, Shiro Onozawa, Daisuke Yasui, Shin-ichiro Kumita, Takeshi Fujita, Satoshi Kobayashi. Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma. The Scientific World Journal 2013; 2013(1) doi: 10.1155/2013/479805
|
| 161 |
Sangheun Lee, Beom Kyung Kim, Seung Up Kim, Yehyun Park, Sooyun Chang, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Chae Yoon Chon, Kwang-Hyub Han, Salomon M Stemmer. Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma. PLoS ONE 2013; 8(10): e77240 doi: 10.1371/journal.pone.0077240
|
| 162 |
Wooram Park, Soojeong Cho, Jingran Ji, Robert J. Lewandowski, Andrew C. Larson, Dong-Hyun Kim. Development and Validation of Sorafenib-eluting Microspheres to Enhance Therapeutic Efficacy of Transcatheter Arterial Chemoembolization in a Rat Model of Hepatocellular Carcinoma. Radiology: Imaging Cancer 2021; 3(1): e200006 doi: 10.1148/rycan.2021200006
|
| 163 |
C. E. N. M. Rosenbaum, A. F. van den Hoven, M. N. G. J. A. Braat, M. Koopman, M. G. E. H. Lam, B. A. Zonnenberg, H. M. Verkooijen, M. A. A. J. van den Bosch. Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response. EJNMMI Research 2016; 6(1) doi: 10.1186/s13550-016-0236-1
|
| 164 |
Jing Liang, Yi Bai, Fu-Shuang Ha, Ying Luo, Hui-Ting Deng, Ying-Tang Gao. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2023; 15(1): 1-18 doi: 10.4251/wjgo.v15.i1.1
|
| 165 |
Zeno Sparchez, Pompilia Radu, Adrian Bartos, Iuliana Nenu, Rares Craciun, Tudor Mocan, Adelina Horhat, Mihaela Spârchez, Jean-François Dufour. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?. World Journal of Gastrointestinal Oncology 2021; 13(12): 1896-1918 doi: 10.4251/wjgo.v13.i12.1896
|
| 166 |
Norihiro Kokudo, Junta Nakajima, Etsuro Hatano, Kazushi Numata. Current Status of Hepatocellular Carcinoma Treatment in Japan. Clinical Drug Investigation 2012; 32(S2): 25 doi: 10.1007/BF03265494
|
| 167 |
Aparna Kalyan, Halla Nimeiri, Laura Kulik. Systemic Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease 2015; 19(2): 421 doi: 10.1016/j.cld.2015.01.009
|
| 168 |
Cristiana Pistol-Tanase, Elena Raducan, Simona Olimpia Dima, Lucian Albulescu, Ionita Alina, Poroschianu Marius, Linda Maria Cruceru, Eleonora Codorean, Teodora Monica Neagu, Irinel Popescu. Assessment of Soluble Angiogenic Markers in Pancreatic Cancer. Biomarkers in Medicine 2008; 2(5): 447 doi: 10.2217/17520363.2.5.447
|
| 169 |
Nathan X. Chai, Julius Chapiro. Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. Seminars in Interventional Radiology 2020; 37(05): 456 doi: 10.1055/s-0040-1719186
|
| 170 |
Bin-Yan Zhong, Zhi-Ping Yan, Jun-Hui Sun, Lei Zhang, Zhong-Heng Hou, Min-Jie Yang, Guan-Hui Zhou, Wan-Sheng Wang, Zhi Li, Peng Huang, Shen Zhang, Xiao-Li Zhu, Cai-Fang Ni. Prognostic Performance of Albumin–Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.525461
|
| 171 |
Robert J. Lewandowski, Jessica M. Andreoli, Ryan Hickey, Joseph R. Kallini, Ahmed Gabr, Talia Baker, Sheetal Kircher, Riad Salem, Laura Kulik. Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. Journal of Vascular and Interventional Radiology 2016; 27(9): 1329 doi: 10.1016/j.jvir.2016.03.043
|
| 172 |
Ligang Chen, Yifei Zheng, Hongjian Zhang, Heng Pan, Qiusong Liu, Xu Zhou, Wei Wei, Yun Liu, Maochuan Zhen, Jinling Wang, Jianyin Zhou, Yilin Zhao. Comparative analysis of tumor‑associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study. Oncology Letters 2018; doi: 10.3892/ol.2018.9055
|
| 173 |
James Ronald, Andrew B. Nixon, Daniele Marin, Rajan T. Gupta, Gemini Janas, Willa Chen, Paul V. Suhocki, Waleska Pabon-Ramos, David R. Sopko, Mark D. Starr, John C. Brady, Herbert I. Hurwitz, Charles Y. Kim. Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma. Radiology 2017; 285(1): 311 doi: 10.1148/radiol.2017162555
|
| 174 |
Stephen L Chan, Tony Mok. Targeted therapy for hepatocellular carcinoma: current status and future direction. Clinical Investigation 2013; 3(1): 83 doi: 10.4155/cli.12.132
|
| 175 |
Xinhua Zou, Qingyu Xu, Ran You, Guowen Yin. Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features. Cancer Medicine 2023; 12(10): 11315 doi: 10.1002/cam4.5841
|
| 176 |
Chun-Hsiang Wang, Keh-Cherng Wey, Lein-Ray Mo, Kuo-Kwan Chang, Ruey-Chang Lin, Jen-Juan Kuo. Current Trends and Recent Advances in Diagnosis, Therapy, and Prevention of Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention 2015; 16(9): 3595 doi: 10.7314/APJCP.2015.16.9.3595
|
| 177 |
Celia Pamela Corona-Villalobos, Vivek Gowdra Halappa, Jean-Francois H. Geschwind, Susanne Bonekamp, Diane Reyes, David Cosgrove, Timothy M Pawlik, Ihab R Kamel. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. European Radiology 2015; 25(2): 380 doi: 10.1007/s00330-014-3412-6
|
| 178 |
Katrin Fuchs, Pierre E. Bize, Alban Denys, Gerrit Borchard, Olivier Jordan. Sunitinib-eluting beads for chemoembolization: Methods for in vitro evaluation of drug release. International Journal of Pharmaceutics 2015; 482(1-2): 68 doi: 10.1016/j.ijpharm.2014.11.041
|
| 179 |
Kurt Mauer, Ryan O’Kelley, Nishant Podda, Siobhan Flanagan, Sameer Gadani. New Treatment Modalities for Hepatocellular Cancer. Current Gastroenterology Reports 2015; 17(5) doi: 10.1007/s11894-015-0442-4
|
| 180 |
Riccardo Lencioni, Laura Crocetti. Image-Guided Cancer Therapy. 2013; : 339 doi: 10.1007/978-1-4419-0751-6_24
|
| 181 |
Jason Pe, Bongseo Choi, Hyunjun Choi, Soon Woo Kwon, Dong-Hyun Kim. Preclinical Therapeutic Evaluation of Lenvatinib-Eluting Microspheres for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma. CardioVascular and Interventional Radiology 2022; 45(12): 1834 doi: 10.1007/s00270-022-03242-8
|
| 182 |
Su Jong Yu, Jung-Hwan Yoon. Molecular targeted therapy with transarterial chemoembolization. Gastrointestinal Intervention 2013; 2(2): 78 doi: 10.1016/j.gii.2013.09.012
|
| 183 |
Nan Li, Bin Chen, Run Lin, Ni Liu, Hai-tao Dai, Ke-yu Tang, Jian-yong Yang, Yong-hui Huang. The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats. Cancer Chemotherapy and Pharmacology 2018; 81(1): 207 doi: 10.1007/s00280-017-3493-4
|
| 184 |
Yee Chao, Young‐Hwa Chung, Guohong Han, Jung‐Hwan Yoon, Jijin Yang, Jianhua Wang, Guo‐Liang Shao, Byung Ik Kim, Teng‐Yu Lee. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial. International Journal of Cancer 2015; 136(6): 1458 doi: 10.1002/ijc.29126
|
| 185 |
Wolfgang Sieghart, Matthias Pinter, Michael Reisegger, Christian Müller, Ahmed Ba-Ssalamah, Johannes Lammer, Markus Peck-Radosavljevic. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. European Radiology 2012; 22(6): 1214 doi: 10.1007/s00330-011-2368-z
|
| 186 |
L. Zhou, J. Li, D.-L. Ai, J.-L. Fu, X.-M. Peng, L.-Z. Zhang, J.-Y. Wang, Y. Zhao, B. Yang, Q. Yu, C.-Z. Liu, H.-M. Wang. Enhanced Therapeutic Efficacy of Combined Use of Sorafenib and Transcatheter Arterial Chemoembolization for Treatment of Advanced Hepatocellular Carcinoma. Japanese Journal of Clinical Oncology 2014; 44(8): 711 doi: 10.1093/jjco/hyu068
|
| 187 |
Yee Chao, Chen-Yi Wu, Chen-Yu Kuo, Jack P. Wang, Jiing-Chyuan Luo, Chien-Hui Kao, Rheun-Chuan Lee, Wei-Ping Lee, Chung-Pin Li. Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. Hepatology International 2013; 7(3): 883 doi: 10.1007/s12072-012-9409-9
|
| 188 |
Masatoshi Kudo, Kazuomi Ueshima, Stephan Chan, Tomohiro Minami, Hirokazu Chishina, Tomoko Aoki, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Mamoru Takenaka, Toshiharu Sakurai, Tomohiro Watanabe, Masahiro Morita, Chikara Ogawa, Yoshiyuki Wada, Masafumi Ikeda, Hiroshi Ishii, Namiki Izumi, Naoshi Nishida. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study. Cancers 2019; 11(8): 1084 doi: 10.3390/cancers11081084
|
| 189 |
Riccardo Lencioni, Laura Crocetti. Local-Regional Treatment of Hepatocellular Carcinoma. Radiology 2012; 262(1): 43 doi: 10.1148/radiol.11110144
|
| 190 |
K. Takayasu. Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective. Japanese Journal of Clinical Oncology 2012; 42(4): 247 doi: 10.1093/jjco/hys020
|
| 191 |
Michael C. Soulen, Govindarajan Narayanan, Ursina Teitelbaum. Interventional Oncology. 2016; : 148 doi: 10.1017/CBO9781107338555.017
|
| 192 |
Ender G. Yegin, Aydos Siykhymbayev, Fatih Eren, Nural Bekiroglu, Osman Cavit Ozdogan. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. Annals of Hepatology 2013; 12(6): 915 doi: 10.1016/S1665-2681(19)31297-9
|
| 193 |
Changyou Jing, Jianjun Li, Chunwang Yuan, Caixia Hu, Liang Ma, Jiasheng Zheng, Yonghong Zhang. Therapeutic analysis of 632 cases treated by transcatheter arterial chemoembolization combined with ablation in hepatocellular carcinoma: A retrospective study. European Journal of Radiology 2024; 178: 111619 doi: 10.1016/j.ejrad.2024.111619
|
| 194 |
Shuang Liu, Hui Li, Lei Guo, Bo Zhang, Binghai Zhou, Wentao Zhang, Jian Zhou, Jia Fan, Qinghai Ye. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion. The Oncologist 2019; 24(4): 513 doi: 10.1634/theoncologist.2018-0305
|
| 195 |
Maen Abdelrahim, David Victor, Abdullah Esmail, Sudha Kodali, Edward A. Graviss, Duc T. Nguyen, Linda W. Moore, Ashish Saharia, Robert McMillan, Joy N. Fong, Ahmed Uosef, Mahmoud Elshawwaf, Kirk Heyne, Rafik M. Ghobrial. Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience. Cancers 2022; 14(3): 650 doi: 10.3390/cancers14030650
|
| 196 |
Aušra Bankauskaitė, Alvydas Česas, Algimatas Šimkaitis, Loreta Malinauskienė. Transarterial Chemoembolization With Doxorubicineluting Microspheres: Single-Center Review Of Safety Profile. Sveikatos mokslai 2016; 26(5): 48 doi: 10.5200/sm-hs.2016.071
|
| 197 |
Matthew Man Pok Lee, Landon Long Chan, Stephen Lam Chan. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma. Journal of Liver Cancer 2023; 23(2): 262 doi: 10.17998/jlc.2023.07.17
|
| 198 |
Masatoshi Kudo, Guohong Han, Richard S. Finn, Ronnie T.P. Poon, Jean-Frederic Blanc, Lunan Yan, Jijin Yang, Ligong Lu, Won-Young Tak, Xiaoping Yu, Joon-Hyeok Lee, Shi-Ming Lin, Changping Wu, Tawesak Tanwandee, Guoliang Shao, Ian B. Walters, Christine Dela Cruz, Valerie Poulart, Jian-Hua Wang. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology 2014; 60(5): 1697 doi: 10.1002/hep.27290
|
| 199 |
Louise C. Connell, James J. Harding, Ghassan K. Abou-Alfa. Advanced Hepatocellular Cancer: the Current State of Future Research. Current Treatment Options in Oncology 2016; 17(8) doi: 10.1007/s11864-016-0415-3
|
| 200 |
Panuwat Promsorn, Takashi Yamaguchi, Hisashi Kosaka, Kazunori Aoi, Katsunori Yoshida, Hideyuki Matsushima, Kosuke Matsui, Shinji Shimoda, Masaki Kaibori, Makoto Naganuma. Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib. Molecular and Clinical Oncology 2024; 21(3) doi: 10.3892/mco.2024.2761
|
| 201 |
Maria Tampaki, Polyxeni P Doumba, Melanie Deutsch, John Koskinas. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. World Journal of Hepatology 2015; 7(14): 1834-1842 doi: 10.4254/wjh.v7.i14.1834
|
| 202 |
Joshua L. Weintraub, Riad Salem. Treatment of Hepatocellular Carcinoma Combining Sorafenib and Transarterial Locoregional Therapy: State of the Science. Journal of Vascular and Interventional Radiology 2013; 24(8): 1123 doi: 10.1016/j.jvir.2013.01.494
|
| 203 |
Stephen L. Chan, Tony Mok, Brigette B. Y. Ma. Management of Hepatocellular Carcinoma: Beyond Sorafenib. Current Oncology Reports 2012; 14(3): 257 doi: 10.1007/s11912-012-0233-0
|
| 204 |
A.H. Mahnken. Transarterielle ablative Therapien des hepatozellulären Karzinoms. Der Radiologe 2014; 54(7): 685 doi: 10.1007/s00117-014-2655-1
|
| 205 |
Haohao Lu, Bin Liang, Chuansheng Zheng, Xiangwen Xia. Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-13179-5
|
| 206 |
Masatoshi Kudo. Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial. Liver Cancer 2018; 7(3): 225 doi: 10.1159/000492535
|
| 207 |
Yoshitaka Inaba, Fumihiko Kanai, Takeshi Aramaki, Takanobu Yamamoto, Toshihiro Tanaka, Koichiro Yamakado, Shuichi Kaneko, Masatoshi Kudo, Kazuho Imanaka, Shinichi Kora, Norifumi Nishida, Nobuyuki Kawai, Hiroshi Seki, Osamu Matsui, Hitoshi Arioka, Yasuaki Arai. A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. European Journal of Cancer 2013; 49(13): 2832 doi: 10.1016/j.ejca.2013.05.011
|
| 208 |
Ann Lii Cheng, Deepak Amarapurkar, Yee Chao, Pei‐Jer Chen, Jean‐François Geschwind, Khean L. Goh, Kwang‐Hyub Han, Masatoshi Kudo, Han Chu Lee, Rheun‐Chuan Lee, Laurentius A. Lesmana, Ho Yeong Lim, Seung Woon Paik, Ronnie T. Poon, Chee‐Kiat Tan, Tawesak Tanwandee, Gaojun Teng, Joong‐Won Park. Re‐evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver International 2014; 34(2): 174 doi: 10.1111/liv.12314
|
| 209 |
Eleni Liapi, Jean-Francois H. Geschwind. Intra-Arterial Therapies for Hepatocellular Carcinoma: Where Do We Stand?. Annals of Surgical Oncology 2010; 17(5): 1234 doi: 10.1245/s10434-010-0977-4
|
| 210 |
Yan-Yu Wang, Xu Yang, Yun-Chao Wang, Jun-Yu Long, Hui-Shan Sun, Yi-Ran Li, Zi-Yu Xun, Nan Zhang, Jing-Nan Xue, Cong Ning, Jun-Wei Zhang, Cheng-Pei Zhu, Long-Hao Zhang, Xiao-Bo Yang, Hai-Tao Zhao. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. World Journal of Gastroenterology 2023; 29(10): 1470 doi: 10.3748/wjg.v29.i10.1470
|
| 211 |
Ewa Janczewska-Kazek, Bogdan Marek, Dariusz Kajdaniuk, Halina Borgiel-Marek. Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-β1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C. World Journal of Gastroenterology 2006; 12(6): 961-965 doi: 10.3748/wjg.v12.i6.961
|
| 212 |
Sangheun Lee, Jung Hyun Kang, Do Young Kim, Sang Hoon Ahn, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Kwang-Hyub Han. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. Hepatology International 2017; 11(3): 292 doi: 10.1007/s12072-017-9792-3
|
| 213 |
J.R. Strosberg, J.M. Weber, J. Choi, T.L. Campos, T.L. Valone, G. Han, M.J. Schell, L.K. Kvols. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Annals of Oncology 2012; 23(9): 2335 doi: 10.1093/annonc/mdr614
|
| 214 |
Yong Li, You-Bing Zheng, Wei Zhao, Bing Liu, Bao-Shan Hu, Xu He, Jian-Wen Huang, Li-Gong Lu. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. Medical Oncology 2013; 30(4) doi: 10.1007/s12032-013-0730-5
|
| 215 |
Eleni Liapi, Jean-Francois H. Geschwind. Vascular Embolotherapy. Medical Radiology 2006; : 221 doi: 10.1007/3-540-33257-X_17
|
| 216 |
Ralph Drewes, Constanze Heinze, Maciej Pech, Maciej Powerski, Katja Woidacki, Andreas Wienke, Alexey Surov, Jazan Omari. Apparent Diffusion Coefficient Can Predict Therapy Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization. Digestive Diseases 2022; 40(5): 596 doi: 10.1159/000520716
|
| 217 |
Simon Chun Ho Yu, Joyce Wai Yi Hui, Edwin Pun Hui, Stephen Lam Chan, Kit Fai Lee, Frankie Mo, John Wong, Brigette Ma, Paul Lai, Tony Mok, Winnie Yeo. Unresectable Hepatocellular Carcinoma: Randomized Controlled Trial of Transarterial Ethanol Ablation versus Transcatheter Arterial Chemoembolization. Radiology 2014; 270(2): 607 doi: 10.1148/radiol.13130498
|
| 218 |
Kai Wei, Meng Wang, Wei Zhang, Han Mu, Tian-Qiang Song. Neutrophil–lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Medical Oncology 2014; 31(6) doi: 10.1007/s12032-014-0969-5
|
| 219 |
Shinji Osada, Hisashi Imai, Hiroyuki Tomita, Yasuharu Tokuyma, Naoki Okumura, Fumio Sakashita, Kenichi Nonoka, Yasuyuki Sugiyama. Vascular endothelial growth factor protects hepatoma cells against oxidative stress‐induced cell death. Journal of Gastroenterology and Hepatology 2006; 21(6): 988 doi: 10.1111/j.1440-1746.2006.04223.x
|
| 220 |
Cressida Bowyer, Andrew L. Lewis, Andrew W. Lloyd, Gary J. Phillips, Wendy M. Macfarlane. Hypoxia as a target for drug combination therapy of liver cancer. Anti-Cancer Drugs 2017; 28(7): 771 doi: 10.1097/CAD.0000000000000516
|
| 221 |
Khaled Farid, Hatem Elalfy, Salwa M. Abo El-khair, Hoda Elgamal, Tarek Besheer, Ali Elmokadem, Walaa Shabana, Sally Abed, Mohamed Elegezy, Ahmed Abd El-khalek, Ahmed El-Morsy, Amr Negm, Ayman Z. Elsamanoudy, Basem El deek, Talal Amer, Mahmoud El-Bendary. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. Expert Review of Gastroenterology & Hepatology 2020; 14(12): 1203 doi: 10.1080/17474124.2020.1823215
|
| 222 |
Chunping Wang, Yinying Lu, Yan Chen, Yongyi Feng, Linjing An, Xinzhen Wang, Shuhui Su, Wenlin Bai, Lin Zhou, Yongping Yang, Dongping Xu. Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study. Clinical & Experimental Metastasis 2009; 26(7): 839 doi: 10.1007/s10585-009-9283-6
|
| 223 |
Renumathy Dhanasekaran, Roniel Cabrera. Primary Liver Cancer. 2012; : 263 doi: 10.1007/978-1-61779-863-4_14
|
| 224 |
Gang Deng, Deng-Ling Zhao, Guang-Chao Li, Hui Yu, Gao-Jun Teng. Combination Therapy of Transcatheter Arterial Chemoembolization and Arterial Administration of Antiangiogenesis on VX2 Liver Tumor. CardioVascular and Interventional Radiology 2011; 34(4): 824 doi: 10.1007/s00270-011-0179-x
|